A registration-directed phase II trial of AFM13, a CD30/CD16A bispecific antibody, in CD30-positive PTCL or transformed mycoses fungoides, has completed enrollment (NCT04101331) [35]. Here, TNFRSF8 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.